PubMed Health⌕ Search

Biomedical subjects

Raedah Al-Fadhli

Publications and source records attributed to Raedah Al-Fadhli.

7 recordsLinked to original sources
PubMed2006

Congenital malformations among 911 newborns conceived after infertility treatment with letrozole or clomiphene citrate.

OBJECTIVE: To evaluate the incidence of congenital malformations among offspring of mothers who conceived with clomiphene citrate (CC) or with letrozole treatment for infertility. DESIGN: Retrospective study. SETTING: 5 fertility centers in Canada. PATIENTS: 911 newborns from women who conceived following CC or letrozole treatment. INTERVENTIONS: Examination of medical files of both mother and newborn, and cross-checked with the parents by telephone calls. MAIN OUTCOME MEASURES: Identified major and minor congenital malformations, birth weight, age of the mother, and type of treatment that led to the conception. RESULTS: Overall, congenital malformations and chromosomal abnormalities were found in 14 of 514 newborns in the letrozole group (2.4%) and in 19 of 397 newborns in the CC group (4.8%). The major malformation rate in the letrozole group was 1.2% (6/514) and in the CC group was 3.0% (12/397). One newborn in the letrozole group was found to have a ventricular septal defect (0.2%) compared to 4 newborns in the CC group (1.0%). In addition, the rate of all congenital cardiac anomalies was significantly higher (P: 0.02) in the CC group (1.8%) compared to the letrozole group (0.2%). CONCLUSION: There was no difference in the overall rates of major and minor congenital malformations among newborns from mothers who conceived after letrozole or CC treatments. However, it appears that congenital cardiac anomaly is less frequent in the letrozole group. The concern that letrozole use for ovulation induction could be teratogenic is unfounded based on our data.

Adult↗
PubMed2006

A randomized trial of superovulation with two different doses of letrozole.

OBJECTIVE: The aim of this study was to evaluate the effects of either a 2.5-mg or a 5-mg daily dose of letrozole in women undergoing superovulation and intrauterine insemination (IUI). DESIGN: Prospective randomized trial. SETTING: Academic teaching hospital. PATIENT(S): Women <40 years old, with patent fallopian tubes and infertility of >1 year in duration. INTERVENTION(S): Patients were randomized into either a 2.5-mg dose of letrozole (34 patients) or a 5-mg dose of letrozole (38 patients) daily for 5 days. When the leading follicle reached 18 mm in diameter, ovulation was triggered by an injection of hCG and IUI was performed 24 and 48 hours later. MAIN OUTCOME MEASURE(S): The number of follicles, endometrial thickness, and pregnancy rate. RESULT(S): Compared with those treated with 2.5 mg of letrozole, the total number of follicles was significantly higher in patients receiving 5 mg of letrozole. No difference in the endometrial thickness was found between the two groups. The pregnancy rate per cycle in patients receiving 5mg of letrozole was statistically higher than in patients receiving 2.5 mg of letrozole (26.3% vs. 5.9%, P<.05). No multiple pregnancies occurred. CONCLUSION(S): Compared with the daily dose of 2.5 mg, 5 mg of letrozole is associated with more follicles and a higher pregnancy rate. It appears that 5 mg daily for 5 days is a preferable letrozole dose for superovulation.

Adult↗
PubMed2006

Effects of different stages of endometriosis on the outcome of in vitro fertilization.

OBJECTIVE: This study was undertaken to evaluate the effects of different stages of endometriosis on the outcome of treatment in an in vitro fertilization (IVF) program. METHODS: This was a retrospective, matched case-control study in an academic tertiary referral centre. The study group consisted of 87 women with laparoscopically diagnosed endometriosis, and the control group consisted of 87 age-matched women undergoing IVF for different reasons. The primary outcomes were duration of stimulation, total gonadotropin dose requirement, peak serum estradiol level, total number of oocytes retrieved, fertilization rate, embryo quality, implantation rate, and clinical pregnancy rate. The effect of obliteration of the cul-de-sac by endometriosis was also evaluated. RESULTS: Women with endometriosis required significantly higher gonadotropin doses than women in the control group (P < 0.01). The fertilization rate was significantly lower for women with endometriosis (P < 0.05), although there was no difference in embryo quality or in the number of embryos transferred. In patients with an obliterated cul-de-sac, fewer oocytes were retrieved than in patients in the control group (P < 0.01). CONCLUSION: The presence of endometriosis, including stages III and IV, does not affect IVF outcome. However, women with endometriosis require more gonadotropin stimulation than those with no endometriosis. Women with an obliterated cul-de-sac have fewer oocytes retrieved than women without obliteration.

Adult↗
PubMed2004

Laparoscopic abdominal cerclage.

Cervical cerclage is an effective treatment of cervical incompetence. It is conventionally done by laparotomy approach. Laparoscopic abdominal cerclage is a less invasive technique that could replace the laparotomy technique. Laparoscopic abdominal cerclage does not require hospitalization, is associated with less pain, and leads to a faster recovery. Laparoscopic abdominal cerclage is equal to or may be better than abdominal cerclage by laparotomy.

Abdomen↗
PubMed2004

Laparoscopic treatment of polycystic ovaries: is its place diminishing?

PURPOSE OF REVIEW: The purpose of this review is to provide a critical discussion on the place of laparoscopic ovarian drilling and medical treatment with metformin for polycystic ovary syndrome. RECENT FINDINGS: Laparoscopic ovarian drilling remains popular. It is associated with an ovulation rate of approximately 80% and a pregnancy rate of 50-60% within 1 year of the procedure. The technique results in a decrease in ovarian stromal blood flow. An increasing amount of data, however, suggests that treatment with metformin is equally as effective. The use of metformin in pregnancy appears to be safe; it decreases the miscarriage rate and possibly the incidence of gestational diabetes. SUMMARY: Laparoscopic ovarian drilling and metformin improve ovulatory dysfunction and pregnancy rate to a similar extent. The advantages of metformin continue beyond conception. It reduces the miscarriage rate and also decreases the likelihood of developing gestational diabetes. A randomized trial comparing the effects of metformin and laparoscopic ovarian drilling in women with polycystic ovary syndrome is recommended.

Female↗